Investors

  • 2021-11-11
    VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON PHASE 2B STUDY OF SACITUZUMAB GOVITECAN CONDUCTED IN CHINA OF PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER MEETS PRIMARY OVERALL RESPONSE RATE ENDPOINT
  • 2021-11-08
    (1) VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE; and (2) SUPPLEMENTAL INFORMATION IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2020
  • 2021-11-05
    NEXT DAY DISCLOSURE RETURN
  • 2021-11-03
    NEXT DAY DISCLOSURE RETURN
  • 2021-11-03
    MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED OCTOBER 30, 2021
  • 2021-11-02
    NEXT DAY DISCLOSURE RETURN
  • 2021-11-01
    NEXT DAY DISCLOSURE RETURN
  • 2021-10-30
    NEXT DAY DISCLOSURE RETURN
  • 2021-10-28
    NEXT DAY DISCLOSURE RETURN
  • 2021-10-27
    NEXT DAY DISCLOSURE RETURN
 Copyright Everest Medicines 2020  云顶药业(苏州)有限公司 苏ICP备20038571号 |  Terms of Use |  Privacy Policy |  Disclaimers

沪公网安备 31010602006477号